GILEAD SCIENCES SL
🇪🇸Spain
- Country
- 🇪🇸Spain
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
(ARTEMIS-IPF) Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF
- First Posted Date
- 2008-10-08
- Last Posted Date
- 2014-04-08
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 494
- Registration Number
- NCT00768300
- Locations
- 🇺🇸
The Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸University of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
Aztreonam for Inhalation Solution vs Tobramycin Inhalation Solution in Patients With Cystic Fibrosis & Pseudomonas Aeruginosa
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-09-23
- Last Posted Date
- 2011-07-04
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 274
- Registration Number
- NCT00757237
Safety, Tolerability, and Antiviral Activity of 24 or 48 Weeks of GS-9190 in Combination With Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-08-29
- Last Posted Date
- 2013-11-05
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 252
- Registration Number
- NCT00743795
Rollover Study Protocol for Pediatric Patients in South Africa for Continued Access to Emtricitabine
- First Posted Date
- 2008-08-28
- Last Posted Date
- 2018-04-26
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 50
- Registration Number
- NCT00743340
- Locations
- 🇿🇦
Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital, Soweto, South Africa
🇿🇦Themba Lethu Clinic, Helen Joseph Hospital, Westdene, Johannesburg, South Africa
Safety, Tolerability, Pharmacokinetics and Activity of GS-9450 in Adults With Non-Alcoholic Steatohepatitis (NASH)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-08-25
- Last Posted Date
- 2014-02-04
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 124
- Registration Number
- NCT00740610
Tenofovir Disoproxil Fumarate (Tenofovir DF) Versus Emtricitabine/Tenofovir DF in Subjects Resistant to Lamivudine
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-08-19
- Last Posted Date
- 2016-03-11
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 280
- Registration Number
- NCT00737568
A Study to Evaluate Tenofovir Disoproxil Fumarate (DF) in Asian-American Adults With Chronic Hepatitis B Infection
- First Posted Date
- 2008-08-15
- Last Posted Date
- 2011-12-05
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 90
- Registration Number
- NCT00736190
Evaluation of Tenofovir Disoproxil Fumarate in Adolescents With Chronic Hepatitis B Infection
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-08-14
- Last Posted Date
- 2016-09-01
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 106
- Registration Number
- NCT00734162
- Locations
- 🇺🇸
Riley Hospital for Children, Indianapolis, Indiana, United States
🇫🇷Hopital Femmes Meres Enfants, Bron Cedex, France
🇪🇸Hospital Universitario De Getafe, Madrid, Spain
Evaluation of the Safety, Tolerability, Pharmacokinetics, and Activity of GS-9450 in Subjects With Chronic HCV
- First Posted Date
- 2008-07-31
- Last Posted Date
- 2014-06-19
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 33
- Registration Number
- NCT00725803
Safety and Efficacy Study of Switching From Epzicom to Truvada
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-07-29
- Last Posted Date
- 2012-05-28
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 312
- Registration Number
- NCT00724711
- Locations
- 🇺🇸
Peter J. Ruane, MD, Inc., Los Angeles, California, United States
🇺🇸Anthony M Mills, MD, Los Angeles, California, United States
🇺🇸Orange Coast Medical Group, Newport Beach, California, United States
© Copyright 2024. All Rights Reserved by MedPath